Thirdrockventures

{
  "id": "atm_crawl_b770d08a7322145f",
  "kind": "LocalBusiness",
  "name": "Thirdrockventures",
  "parent_id": "atm_geoid_06041",
  "depth": null,
  "facts": {
    "name": "Thirdrockventures",
    "crawl": true,
    "email": null,
    "phone": "4157663600",
    "address": null,
    "website": "https://thirdrockventures.com/",
    "category": null,
    "found_on": "thirdrockventures.com",
    "found_url": "https://www.thirdrockventures.com/people/mary-lynne-hedley"
  },
  "source_id": "src_5ad3cc6df1d1e72a55ad",
  "updated_at": "2026-10-14T07:07:53.155Z",
  "type": "Feature",
  "geometry": null,
  "links": {
    "self": "https://miscsubjects.com/atlas/atoms/atm_crawl_b770d08a7322145f",
    "children": "https://miscsubjects.com/atlas/atoms/atm_crawl_b770d08a7322145f/children",
    "descendants": "https://miscsubjects.com/atlas/atoms/atm_crawl_b770d08a7322145f/descendants",
    "inside": "https://miscsubjects.com/atlas/atoms/atm_crawl_b770d08a7322145f/inside",
    "graph": "https://miscsubjects.com/atlas/graph?start=atm_crawl_b770d08a7322145f"
  },
  "ancestors": [
    {
      "id": "atm_geoid_06041",
      "kind": "County",
      "name": "Marin County",
      "up": 1
    },
    {
      "id": "atm_geoid_06",
      "kind": "State",
      "name": "California",
      "up": 2
    },
    {
      "id": "atm_geoid_us",
      "kind": "Country",
      "name": "United States",
      "up": 3
    }
  ],
  "children_by_kind": [],
  "edges_out": [
    {
      "rel": "has_profile",
      "id": "atm_prof_0c0476d20161c61f9848",
      "kind": "Profile",
      "name": "linkedin: in/lee-venezia-365314ba",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_1174c7ea63bf1878b4d6",
      "kind": "Profile",
      "name": "x: thirdrockv",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_603d3c9f0f3633c5344e",
      "kind": "Profile",
      "name": "linkedin: in/andreavanelsas",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_62dcfdc3ec664db5d5ea",
      "kind": "Profile",
      "name": "linkedin: in/jigar-raythatha",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_7e63d8730f11d67960cf",
      "kind": "Profile",
      "name": "linkedin: in/angeloseverino",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_a95cebc00d592cc169f2",
      "kind": "Profile",
      "name": "linkedin: in/sarah-devos-ba777763",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_bb90df4d055f59920458",
      "kind": "Profile",
      "name": "linkedin: in/jesper-gromada-b3787042",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_bbe5ab2242200db6e699",
      "kind": "Profile",
      "name": "linkedin: in/abbie-celniker-277a356",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_c916b2df46af108cf28a",
      "kind": "Profile",
      "name": "youtube: UCN__nHDMJUkYFjpsXru9F1g",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_e91c4bd373d261876513",
      "kind": "Profile",
      "name": "linkedin: in/david-moller-6b58132a",
      "share": null
    },
    {
      "rel": "has_profile",
      "id": "atm_prof_f6c5408ece14526e5aa5",
      "kind": "Profile",
      "name": "linkedin: company/third-rock-ventures",
      "share": null
    }
  ],
  "edges_in": [
    {
      "rel": "site_of",
      "id": "atm_site_ebadf28318d4c78c38f3",
      "kind": "Website",
      "name": "Thirdrockventures",
      "share": null
    }
  ],
  "edges_in_total": 1,
  "external_ids": [],
  "source": {
    "id": "src_5ad3cc6df1d1e72a55ad",
    "url": null,
    "license": "public web pages, robots.txt honoured",
    "read_at": "2026-10-13T23:21:09.844Z",
    "sha256": "208b3244e04e88f503da63917fd963b3f4f5a70528be355db4d5f625a8a28164"
  },
  "observations": [
    {
      "service": "WEBSITE_EXTRACT",
      "fetched_at": {},
      "query": {
        "job": "website:atm_crawl_b770d08a7322145f",
        "url": "https://thirdrockventures.com/"
      },
      "payload": {
        "title": "Thirdrockventures | Home Page",
        "emails": [],
        "jsonld": [
          {
            "@graph": [
              {
                "url": "https://www.thirdrockventures.com/",
                "name": "Thirdrockventures",
                "@type": "WebPage",
                "image": {
                  "url": "https://finicky-rhea.transforms.svdcdn.com/production/TRV_primary_2color_02.jpg?w=1200&h=630&q=82&auto=format&fit=crop&dm=1573235129&s=f4a5c506db57a6370e55d0685ebae42e",
                  "@type": "ImageObject"
                },
                "author": {
                  "@id": "#identity"
                },
                "creator": {
                  "@id": "#creator"
                },
                "headline": "Home Page",
                "publisher": {
                  "@id": "#creator"
                },
                "inLanguage": "en-us",
                "description": "Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.",
                "dateModified": "2026-09-17T11:54:45-07:00",
                "copyrightYear": "2019",
                "datePublished": "2019-04-10T07:27:00-07:00",
                "copyrightHolder": {
                  "@id": "#identity"
                },
                "mainEntityOfPage": "https://www.thirdrockventures.com/"
              },
              {
                "@id": "#identity",
                "@type": "Organization"
              },
              {
                "@id": "#creator",
                "@type": "Organization"
              },
              {
                "name": "Breadcrumbs",
                "@type": "BreadcrumbList",
                "description": "Breadcrumbs list",
                "itemListElement": [
                  {
                    "item": "https://www.thirdrockventures.com/",
                    "name": "Home Page",
                    "@type": "ListItem",
                    "position": 1
                  }
                ]
              }
            ],
            "@context": "http://schema.org/"
          }
        ],
        "phones": [
          "(617) 585-2000",
          "(415) 766-3600"
        ],
        "public": true,
        "sha256": "f13f996c35de4b827db2c44b64926143fbabe1820a2fadf5ae79aeb19c8f8a21",
        "excerpt": " Thirdrockventures | Home Page Approach People Portfolio Careers News Contact Approach People Portfolio Careers News Contact Discover. Launch. Build. Transform. ● Recent Highlights Marea Therapeutics Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement. Press Release Merida Biosciences Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Press Release Revolution Medicines Revolution Medicines receives FDA approval for RASONQUE™ (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE™ is the first broad RAS-targeted medicine in metastatic pancreatic cancer and is positioned to become a new standard of care. RASONQUE™ (daraxonrasib) Tango Therapeutics Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer Press release Candid Therapeutics UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers Press release Otarmeni™ Otarmeni™ (lunsotogene parvec-cwha) an original asset from Decibel Therapeutics, (acquired by Regeneron in 2023) receives FDA approval. Otarmeni™ is the first and only gene therapy for genetic hearing loss in pediatric and adult patients. The approval signals a new era in treatment of genetic forms of hearing loss, where reinstating 24/7 natural hearing is now possible. Otarmeni™ (lunsotogene parvec-cwha) Synnovation Therapeutics Novartis to acquire Synnovation Therapeutics’s pan-mutant selective PI3Kα inhibitor program Press release Aqvesme™ AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Thalassemia is a debilitating disease that demands lifelong management and vigilant monitoring for many life-threatening complications, such as blood clots, heart disease, and liver disease. Mitapivat was first approved in 2022 and is marketed as PYRUKYND for the PK deficiency indication. Aqvesme™ (mitapivat) Syremis Therapeutics Syremis is developing novel medicines to make a profound impact on the treatment of mental health. Syremis Therapeutics INLEXZO™ INLEXZO™ (gemcitabine intravesical system) an original asset from Taris Bio, (acquired by Johnson & Johnson in 2019) receives FDA approval. INLEXZO™ is a new, potentially practice-changing approach for treating patients with certain types of bladder cancer, addressing the need for additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery. INLEXZO™ (gemcitabine intravesical system) Azalea Therapeutics Azalea is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo. Azalea Therapeutics 19 Years 73 Portfolio Companies 27 Marketed Products 1 Priority: Patients 201 Brookline Ave Suite 1401 Boston, MA 02215 P (617) 585-2000 499 Illinois Street Suite 110 San Francisco, CA 94158 P (415) 766-3600 Privacy Policy Terms ",
        "source_url": "https://www.thirdrockventures.com/",
        "observed_at": "2026-10-14T07:25:53.833Z"
      }
    }
  ],
  "edges_out_total": 11
}